Literature DB >> 28762753

Migraine in mitochondrial disorders: Prevalence and characteristics.

Catello Vollono1, Guido Primiano1, Giacomo Della Marca1, Anna Losurdo2, Serenella Servidei1.   

Abstract

Background Migraine is a well-known feature of mitochondrial disorders (MDs). However, no systematic epidemiological data are available in large populations of patients. Aims The aim of this cross-sectional cohort study was to describe the prevalence and migraine characteristics in a large cohort of patients with mitochondrial encephalomyopathies. Methods We studied 93 consecutive patients with characterised MDs referred to our Neuromuscular Unit during a 12-month period. All patients (age range = 16-78 years; 31 men; 58 progressive external ophthalmoplegia [PEO], 12 myoclonic epilepsy with ragged red fibres [MERRF], eight mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes [MELAS], two mitochondrial neurogastrointestinal encephalomyopathy [MNGIE] and 13 other MDs) underwent a structured diagnostic headache interview using an operational diagnostic tool following the IHS criteria. If they met the criteria for migraine, they were included in the 'Migraine Group'. The other patients were counted in the 'No Migraine Group'. Patient demographic and migraine characteristics were examined. Clinical, neuroradiological and neurophysiological data were compared between groups. Results Migraine was reported in 35.5% of patients. Migraine without aura was the most common headache (81.8%). The migraine group showed younger age ( P < 0.01), increased prevalence of epilepsy ( P = 0.01), myoclonus ( P = 0.03), stroke-like episodes ( P = 0.03) and decreased prevalence of muscle weakness ( P < 0.01). Multivariate analysis showed that migraine was positively associated with absence of muscle weakness ( P = 0.04) and presence of EEG abnormalities ( P = 0.02). Conclusion Migraine has a higher prevalence in MDs compared with general population-based data, independently from genotype or phenotype. Migraine is not merely a phenotypic aspect of specific MDs but is rather the expression of vulnerability of the central nervous system, probably directly related with defects of the respiratory chain.

Entities:  

Keywords:  Mitochondrial diseases; headache; lactic acidosis and stroke-like episodes (MELAS); mitochondrial encephalomyopathy; mitochondrial neurogastrointestinal encephalomyopathy (MNGIE); myoclonic epilepsy with ragged red fibres (MERRF); progressive external ophthalmoplegia (PEO)

Mesh:

Year:  2017        PMID: 28762753     DOI: 10.1177/0333102417723568

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  15 in total

1.  Preventive migraine treatment in mitochondrial diseases: a case report of erenumab efficacy and literature review.

Authors:  Guido Primiano; Eleonora Rollo; Marina Romozzi; Paolo Calabresi; Serenella Servidei; Catello Vollono
Journal:  Neurol Sci       Date:  2022-09-13       Impact factor: 3.830

Review 2.  Brain Energy Deficit as a Source of Oxidative Stress in Migraine: A Molecular Basis for Migraine Susceptibility.

Authors:  Jonathan M Borkum
Journal:  Neurochem Res       Date:  2021-04-30       Impact factor: 3.996

Review 3.  Headache in cerebrovascular diseases.

Authors:  Jiajie Lu; Wei Liu; Hongru Zhao
Journal:  Stroke Vasc Neurol       Date:  2020-03-26

Review 4.  Mitochondrial Neurogastrointestinal Encephalomyopathy: Into the Fourth Decade, What We Have Learned So Far.

Authors:  Dario Pacitti; Michelle Levene; Caterina Garone; Niranjanan Nirmalananthan; Bridget E Bax
Journal:  Front Genet       Date:  2018-12-21       Impact factor: 4.599

5.  The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders.

Authors:  Mirian C H Janssen; Saskia Koene; Paul de Laat; Pleun Hemelaar; Peter Pickkers; Edwin Spaans; Rypko Beukema; Julien Beyrath; Jan Groothuis; Chris Verhaak; Jan Smeitink
Journal:  Clin Pharmacol Ther       Date:  2018-09-03       Impact factor: 6.875

Review 6.  Exploring the Hereditary Nature of Migraine.

Authors:  Charlene Bron; Heidi G Sutherland; Lyn R Griffiths
Journal:  Neuropsychiatr Dis Treat       Date:  2021-04-22       Impact factor: 2.570

7.  The spectrum of neuro-ophthalmologic involvement in mitochondrial disorders is broad.

Authors:  Josef Finsterer
Journal:  Taiwan J Ophthalmol       Date:  2021-07-16

Review 8.  The metabolic face of migraine - from pathophysiology to treatment.

Authors:  Elena C Gross; Marco Lisicki; Dirk Fischer; Peter S Sándor; Jean Schoenen
Journal:  Nat Rev Neurol       Date:  2019-10-04       Impact factor: 42.937

Review 9.  Migraine and neuroinflammation: the inflammasome perspective.

Authors:  Oguzhan Kursun; Muge Yemisci; Arn M J M van den Maagdenberg; Hulya Karatas
Journal:  J Headache Pain       Date:  2021-06-10       Impact factor: 7.277

Review 10.  Nutrients to Improve Mitochondrial Function to Reduce Brain Energy Deficit and Oxidative Stress in Migraine.

Authors:  Michal Fila; Cezary Chojnacki; Jan Chojnacki; Janusz Blasiak
Journal:  Nutrients       Date:  2021-12-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.